wanyu/IteraTeR_v2 huggingface dataset:
Original: 14 November 1988JohannesburgHard (i) Jakob Hlasek7 –6, 4–6, 1–6, 6– 7Loss2.18 June 1989London /Queen's ClubGrass Ivan Lendl6 –4, 3–6, 4– 6Win2.19 November 1989JohannesburgHard (i) Paul Chamberlin6 –4, 7–6, 6– 3Loss3.8 April 1990OrlandoHard Brad Gilbert2 –6, 1– 6Loss4.
Revised: 14 November 1988JohannesburgHard (i) Jakob Hlasek7 –6, 4–6, 1–6, 6– 7Loss2.18 June 1989London /Queen's ClubGrass Ivan Lendl6 –4, 3–6, 4– 6Win2.19 November 1989JohannesburgHard (i) Paul Chamberlin 6 –4, 7–6, 6– 3Loss3.8 April 1990OrlandoHard Brad Gilbert2 –6, 1– 6Loss4.
Edit intent: fluency
Original: 14 November 1988JohannesburgHard (i) Jakob Hlasek7 –6, 4–6, 1–6, 6– 7Loss2.18 June 1989London /Queen's ClubGrass Ivan Lendl6 –4, 3–6, 4– 6Win2.19 November 1989JohannesburgHard (i) Paul Chamberlin6 –4, 7–6, 6– 3Loss3.8 April 1990OrlandoHard Brad Gilbert2 –6, 1– 6Loss4.
Revised: 14 November 1988JohannesburgHard (i) Jakob Hlasek7 –6, 4–6, 1–6, 6– 7Loss2.18 June 1989London /Queen's ClubGrass Ivan Lendl6 –4, 3–6, 4– 6Win2.19 November 1989JohannesburgHard (i) Paul Chamberlin6 –4, 7–6, 6– 3Loss 3. 8 April 1990 Orlando Hard Brad Gilbert 2 –6, 1– 6Loss4.
Edit intent: fluency
Original:  7–6, 6–3Win 14. 1990 Tel-Aviv ,
Revised:  7–6, 6–3Win 14. 1990 Tel Aviv ,
Edit intent: fluency
Original: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando  Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg  Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club  Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg  Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando  Hard Brad Gilbert 2–6, 1–6Loss 4.
Revised: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando , US Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando Hard Brad Gilbert 2–6, 1–6Loss 4.
Edit intent: clarity
Original: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando  Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg  Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club  Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg  Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando  Hard Brad Gilbert 2–6, 1–6Loss 4.
Revised: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg , South Africa Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando Hard Brad Gilbert 2–6, 1–6Loss 4.
Edit intent: clarity
Original: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando  Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg  Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club  Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg  Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando  Hard Brad Gilbert 2–6, 1–6Loss 4.
Revised: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club , UK Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando Hard Brad Gilbert 2–6, 1–6Loss 4.
Edit intent: clarity
Original: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando  Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg  Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club  Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg  Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando  Hard Brad Gilbert 2–6, 1–6Loss 4.
Revised: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg , South Africa Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando Hard Brad Gilbert 2–6, 1–6Loss 4.
Edit intent: clarity
Original: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando  Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg  Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club  Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg  Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando  Hard Brad Gilbert 2–6, 1–6Loss 4.
Revised: ResultW/L DateTournamentSurfaceOpponentScoreWin 1. Mar 1987 Orlando Hard Jimmy Connors 6–3, 3–6, 6–1Loss 1. Nov 1988 Johannesburg Hard (i) Jakob Hlasek 7–6(7–1), 4–6, 1–6, 6–7(4–7)Loss 2. Jun 1989 London/Queen's Club Grass Ivan Lendl 6–4, 3–6, 4–6Win 2. Nov 1989 Johannesburg Hard (i) Paul Chamberlin 6–4, 7–6, 6–3Loss 3. Apr 1990 Orlando , US Hard Brad Gilbert 2–6, 1–6Loss 4.
Edit intent: clarity
Original:  This course has to be renewed every 5 years, or under certain conditions, you have to show that you have at least 1 year of service on board vessels of 200 grt or more within the last 5 years.stcw.org.
Revised:  This course has to be renewed every 5 years, or under certain conditions, you have to show that you have at least 1 year of service on board vessels of 200 grt or more within the last 5 URL
Edit intent: clarity
Original: Maritime Employment Requiremen 
Revised: Maritime Employment Requirement 
Edit intent: fluency
Original: BOSIET Training at South Tyneside College ST   
Revised: BOSIET Training at South Tyneside College STC 
Edit intent: fluency
Original:  This course has to be renewed every 5 years, or under certain conditions, you have to show that you have at least 1 year of service on board vessels of 200 grt or more within the last 5 URL The components generally includes a Fire Prevention and Fire Fighting (Basic Fire fighting) course of 2 days, a Personal Survival Techniques (PST) course of 1.5 days, a Personal Safety and Social Responsibility (PSSR) course of half a day, and, First Aid / CPR (Basic First Aid) course of 1 day.
Revised:  This course has to be renewed every 5 years, or under certain conditions, you have to show that you have at least 1 year of service on board vessels of 200 grt or more within the last 5 years. The components generally includes a Fire Prevention and Fire Fighting (Basic Fire fighting) course of 2 days, a Personal Survival Techniques (PST) course of 1.5 days, a Personal Safety and Social Responsibility (PSSR) course of half a day, and, First Aid / CPR (Basic First Aid) course of 1 day.
Edit intent: fluency
Original:  BOSIET Training at South Tyneside College STC
Edit intent: coherence
Original:  This means the people considered him to have have the ability to either venerate or curse a community, so although he ruled with respect and kindness for his people  they also feared him.
Revised:  This means the people considered him to have the ability to either venerate or curse a community, so although he ruled with respect and kindness for his people they also feared him.
Edit intent: fluency
Original:  This means the people considered him to have have the ability to either venerate or curse a community, so although he ruled with respect and kindness for his people  they also feared him.
Revised:  This means the people considered him to have have the ability to either venerate or curse a community, so although he ruled with respect and kindness for his people , they also feared him.
Edit intent: fluency
Original:  His death was announced on 29 April 2016.
Revised:  The chalk hit the ground on 29 April 2016.
Edit intent: clarity
Original:  Category:1923 births Category:2016 deaths Category:Obas of Benin Category:Alumni of King's College, Cambridge Category:Nigerian civil servants Category:Nigerian royalty Category:Government College, Ibadan alumni Category:Edo people Category:20th-century monarchs in Africa Category:21st-century monarchs in Africa Category:Akenzua fami
Revised:  Category:1923 births Category:Obas of Benin Category:Alumni of King's College, Cambridge Category:Nigerian civil servants Category:Nigerian royalty Category:Government College, Ibadan alumni Category:Edo people Category:20th-century monarchs in Africa Category:21st-century monarchs in Africa Category:Akenzua fami
Edit intent: clarity
Original: Critical Path Institute (C-Path) is an independent, non-profit organization committed to transformational improvement of the drug development process . C-Path has established first-of-its-kind, global consortia that currently include over 1, 000 scientists from government regulatory and research agencies, academia, patient advocacy organizations, and forty one major biopharmaceutical companies.
Revised: Critical Path Institute (C-Path) is a nonprofit organization created to improve the drug development process . C-Path has established first-of-its-kind, global consortia that currently include over 1, 000 scientists from government regulatory and research agencies, academia, patient advocacy organizations, and forty one major biopharmaceutical companies.
Edit intent: clarity
Original: Critical Path Institute (C-Path) is an independent, non-profit organization committed to transformational improvement of the drug development process . C-Path has established first-of-its-kind, global consortia that currently include over 1, 000 scientists from government regulatory and research agencies, academia, patient advocacy organizations, and forty one major biopharmaceutical companies.
Revised: Critical Path Institute (C-Path) is an independent, non-profit organization committed to transformational improvement of the drug development process ; its consortia include more than 1, 000 scientists from government regulatory and research agencies, academia, patient advocacy organizations, and forty one major biopharmaceutical companies.
Edit intent: clarity
Original: Critical Path Institute (C-Path) is an independent, non-profit organization committed to transformational improvement of the drug development process . C-Path has established first-of-its-kind, global consortia that currently include over 1, 000 scientists from government regulatory and research agencies, academia, patient advocacy organizations, and forty one major biopharmaceutical companies.
Revised: Critical Path Institute (C-Path) is an independent, non-profit organization committed to transformational improvement of the drug development process . C-Path has established first-of-its-kind, global consortia that currently include over 1, 000 scientists from government regulatory and research agencies, academia, patient advocacy organizations, and biopharmaceutical companies.
Edit intent: clarity
Original:  its consortia include more than 1,600 scientists from government regulatory and research agencies, academia, patient advocacy organizations, and biopharmaceutical companies.
Revised:  its consortia include more than 1,600 scientists from government regulatory and research agencies, academia, patient organizations, and biopharmaceutical companies.
Edit intent: clarity
Original:  Clinical Therapeutics 31.11(2009): 2572-2573 In 2010, only 21 new drugs were approved for URL To address the declining productivity of the pharmaceutical industry, the U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative (CPI) in 2004 , its national strategy for forming collaborations to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.
Revised:  Clinical Therapeutics 31.11(2009): 2572-2573 In 2010, only 21 new drugs were approved for URL The U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative (CPI) in 2004 , its national strategy for forming collaborations to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.
Edit intent: coherence
Original:  Clinical Therapeutics 31.11(2009): 2572-2573 In 2010, only 21 new drugs were approved for URL To address the declining productivity of the pharmaceutical industry, the U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative (CPI) in 2004 , its national strategy for forming collaborations to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.
Revised:  Clinical Therapeutics 31.11(2009): 2572-2573 In 2010, only 21 new drugs were approved for URL To address the declining productivity of the pharmaceutical industry, the U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative in 2004 , its national strategy for forming collaborations to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.
Edit intent: clarity
Original:  Clinical Therapeutics 31.11(2009): 2572-2573 In 2010, only 21 new drugs were approved for URL To address the declining productivity of the pharmaceutical industry, the U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative (CPI) in 2004 , its national strategy for forming collaborations to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.
Revised:  Clinical Therapeutics 31.11(2009): 2572-2573 In 2010, only 21 new drugs were approved for URL To address the declining productivity of the pharmaceutical industry, the U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative (CPI) in 2004 to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.
Edit intent: coherence
Original:  C-Path's creation was designed to fill an essential role as a neutral third party that enables scientists from the regulated industry and international regulatory agencies to work together to establish a faster, safer, and more efficient path through the drug development process.
Revised:  C-Path's creation was designed to fill an essential role as a neutral third party to enable scientists from the regulated industry and international regulatory agencies to work together to establish a faster, safer, and more efficient path through the drug development process.
Edit intent: coherence
Original:  C-Path's creation was designed to fill an essential role as a neutral third party that enables scientists from the regulated industry and international regulatory agencies to work together to establish a faster, safer, and more efficient path through the drug development process.
Revised:  C-Path's creation was designed to fill an essential role as a neutral third party that enables scientists from the regulated industry and international regulatory agencies to work together 
Edit intent: clarity
Original:  Since its launch in 2005, six C-Path consortia—made up of participants from industry, academia , regulatory agencies, and patient advocacy groups —have focused on identifying the best methods for testing drug safety and efficacy, and have shared their data and knowledge about major diseases (clinical trial data, quantitative disease progression models, and biomarkers) .
Revised:  with scientists from academia and patient groups to improve the drug development process .
Edit intent: coherence
Original:  C-Path focuses on work that has been identified as high priority by the FDA and is in the interest of national and global public health . Qualification process C-Path and FDA scientists have worked together to identify the guiding principles for how biomarkers can be scientifically reviewed in order to bring greater efficiency to the drug development process.
Revised:  C-Path focuses on work that has been identified as high priority by the FDA and is in the interest of national and global public health Qualification process C-Path and FDA scientists have worked together to identify the guiding principles for how biomarkers can be scientifically reviewed in order to bring greater efficiency to the drug development process.
Edit intent: fluency
Original:  C-Path focuses on work that has been identified as high priority by the FDA and is in the interest of national and global public health . Qualification process C-Path and FDA scientists have worked together to identify the guiding principles for how biomarkers can be scientifically reviewed in order to bring greater efficiency to the drug development process.
Revised:  C-Path focuses on work that has been identified as high priority by the FDA and is in the interest of national and global public health . , C-Path and FDA scientists have worked together to identify the guiding principles for how biomarkers can be scientifically reviewed in order to bring greater efficiency to the drug development process.
Edit intent: coherence
Original:  This is the process being used by C-Path consortia and others to obtain regulatory decisions on the acceptability of new testing methods in drug development . C-Path consortia C-Path consortia are public/private partnerships that are revolutionizing  the drug development process."
Revised:  This is the process being used by C-Path consortia and others to obtain regulatory decisions on the acceptability of new testing methods in drug development . C-Path Programs C-Path consortia are public/private partnerships that are revolutionizing the drug development process."
Edit intent: fluency
Original:  This is the process being used by C-Path consortia and others to obtain regulatory decisions on the acceptability of new testing methods in drug development . C-Path consortia C-Path consortia are public/private partnerships that are revolutionizing  the drug development process."
Revised:  This is the process being used by C-Path consortia and others to obtain regulatory decisions on the acceptability of new testing methods in drug development . C-Path consortia C-Path consortia are public/private partnerships 16 the drug development process."
Edit intent: clarity
Original:  This is the process being used by C-Path consortia and others to obtain regulatory decisions on the acceptability of new testing methods in drug development . C-Path consortia C-Path consortia are public/private partnerships that are revolutionizing  the drug development process."
Revised:  This is the process being used by C-Path consortia and others to obtain regulatory decisions on the acceptability of new testing methods in drug development . C-Path consortia C-Path consortia are public/private partnerships that are revolutionizing that aim to improve the drug development process."
Edit intent: clarity
Original:  Readers Digest selected C-Path as one of 18 Ideas to Reform Health Care, citing its ability to “bring together the FDA and drug, biotech, and diagnostic companies (many of them fierce competitors) to talk more openly so patients can get safer drugs more quickly and inexpensively.”"18 Ideas to Reform Health Care Now." Reader's Digest, November 2008.
Edit intent: coherence
Original:  The Critical Path to TB Drug Regimens (CPTR) is a collaboration of pharmaceutical companies, government, regulatory, and multilateral agencies, donors, academia, advocates, and NGOs that aims to accelerate the development of new, safe, and highly effective tuberculosis treatment regimens with shortened durations of therapy.
Revised:  The Critical Path to TB Drug Regimens (CPTR) aims to accelerate the development of new, safe, and highly effective tuberculosis treatment regimens with shortened durations of therapy.
Edit intent: coherence
Original:  Joining the Bill Melinda Gates Foundation and the Global Alliance for TB Drug Development (TB Alliance) as CPTR founding organizations, C-Path provides overall program management for this initiative and leads one component, the CPTR Regulatory Science Consortium.
Revised:  Melinda Gates Foundation and the Global Alliance for TB Drug Development (TB Alliance) as CPTR founding organizations, C-Path provides overall program management for this initiative and leads one component, the CPTR Regulatory Science Consortium.
Edit intent: coherence
Original:  Joining the Bill Melinda Gates Foundation and the Global Alliance for TB Drug Development (TB Alliance) as CPTR founding organizations, C-Path provides overall program management for this initiative and leads one component, the CPTR Regulatory Science Consortium.
Revised:  Joining the Bill 
Edit intent: coherence
Original:  If the data support the conclusion that TKV is an early and reliable predictor of subsequent renal failure, C-path will submit a request to the FDA that TKV be qualified as a measure of disease progression that can be used in drug development to test the efficacy of new drugs.
Edit intent: coherence
Original:  Díaz’s fleet then prepared to weigh, except for the Portuguese Ajuda, which attempted to desert its Spanish consorts but was wrecked on Providencia’s reefs.
Revised:  The Spanish fleet then prepared to weigh, except for the Portuguese Ajuda, which attempted to desert its Spanish consorts but was wrecked on Providencia’s reefs.
Edit intent: clarity
Original:  Wattar was called "one of the North African nation’s most prolific Arabic language authors".
Revised:  Ouettar was called "one of the North African nation’s most prolific Arabic language authors".
Edit intent: clarity
Original:  Wattar published his first novel "Al Laz" in 1974.
Revised:  Ouettar published his first novel "Al Laz" in 1974.
Edit intent: clarity
Original: Tahar Ouettar Tahar Ouettar (  1936 – August 12, 2010) was an Algerian writer.
Revised: Tahar Ouettar Tahar Ouettar ( ; 1936 – August 12, 2010) was an Algerian writer.
Edit intent: fluency
Original: Tahar Ouettar Tahar Ouettar (;
Revised: Tahar Ouettar (;
Edit intent: clarity
Original: Basic terms Ideal final result (IFR) - the ultimate idealistic solution of a problem when the desired result is achieved by URL Note that the Ideal Final Result is also an ARIZ term for the formulation of the inventive problem in the form of a Technical Contradiction (IFR-1) and a Physical Contradiction (IFR-2);
Revised: Basic terms Ideal final result (IFR) - the ultimate idealistic solution of a problem when the desired result is achieved by itself. Note that the Ideal Final Result is also an ARIZ term for the formulation of the inventive problem in the form of a Technical Contradiction (IFR-1) and a Physical Contradiction (IFR-2);
Edit intent: clarity
Original: Modifications and derivatives SIT (systematic inventive thinking) & SIT Company - A company developed based on this method USIT (unified structured inventive thinking) TOP-TRIZ (a modern version of further developed and integrated TRIZ methods .) “TOP-TRIZ includes further development of problem formulation and problem modeling, development of Standard Solutions into Standard Techniques, further development of ARIZ and Technology Forecasting.
Revised: Modifications and derivatives SIT (systematic inventive thinking) & SIT Company - A company developed based on this method USIT (unified structured inventive thinking) Top-TRIZ (a modern version of further developed and integrated TRIZ methods .) “TOP-TRIZ includes further development of problem formulation and problem modeling, development of Standard Solutions into Standard Techniques, further development of ARIZ and Technology Forecasting.
Edit intent: fluency
Original:  The 5th International Conference on Systematic Innovation, San Jose, CA, July 16-18, 2014, Proceeding, ISBN 978-986-90782-1-4, Pages 253-282.
Edit intent: coherence
Original: %DIFDELCMD < %DIFDELCMD < %%% URL
Revised: %DIFDELCMD < %DIFDELCMD < %%% )
Edit intent: coherence
Original: Hussain, Syed Shabbir, History of Pakistan Air Force 1947 - 1982.
Revised: Hussain, Syed Shabbir, History of Pakistan Air Force 1947 – 1982.
Edit intent: fluency
Original:  Commands No 9 Squadron: September 1953 to September 1954Hussain, Syed Shabbir, History of Pakistan Air Force 1947 - 1982.
Revised:  Commands No 9 Squadron: September 1953 to September 1954Hussain, Syed Shabbir, History of Pakistan Air Force 1947 – 1982.
Edit intent: fluency